Patents by Inventor Shuping Tong

Shuping Tong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treating hepatitis B virus infections by administering receptor associated protein (RAP)
    Patent number: 10442868
    Abstract: The specification provides compositions and methods of reducing a risk of a HBV infection in a subject and of treating a subject infected with HBV.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 15, 2019
    Assignee: Rhode Island Hospital, A Lifespan-Partner
    Inventors: Jack R. Wands, Jisu Li, Shuping Tong
  • Treating Hepatitus B Virus Infections
    Publication number: 20160024223
    Abstract: The specification provides compositions and methods of reducing a risk of a HBV infection in a subject and of treating a subject infected with HBV.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 28, 2016
    Inventors: Jack R. Wands, Jisu Li, Shuping Tong
  • Hepadnavirus pre-S protein fragments
    Publication number: 20020032307
    Abstract: The invention features fragments of hepadnavirus pre-S protein that bind to viral receptor p120 or p170.
    Type: Application
    Filed: March 27, 2001
    Publication date: March 14, 2002
    Applicant: The General Hospital Corporation, a Massachusetts corporation
    Inventors: Shuping Tong, Jisu Li, Jack R. Wands
  • Hepadnavirus receptor
    Patent number: 6258937
    Abstract: The invention features an hepadnavirus cellular receptor and a nucleic acid sequence that encodes the receptor. The receptor is a 170 kD surface glycoprotein, and is referred to as the p170 receptor.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: July 10, 2001
    Assignee: The General Hospital Corporation
    Inventors: Shuping Tong, Jisu Li, Jack R. Wands
  • Hepadnavirus receptor
    Patent number: 5929220
    Abstract: The invention features a purified nucleic acid that encodes a member of the hepadnavirus family of cellular receptors. The receptor is a 170 kD cell surface glycoprotein, and is referred to as the p170 receptor. The pre-S domain of the duck hepatitis B virus envelope protein binds the p170 receptor at a major neutralizing epitope, within which are two basic amino acids required for virion-receptor interaction.
    Type: Grant
    Filed: July 18, 1996
    Date of Patent: July 27, 1999
    Assignee: The General Hospital Corporation
    Inventors: Shuping Tong, Jisu Li, Jack R. Wands